Form D · Biotechnology
Talaris Therapeutics, Inc.
Louisville, KY · CIK 0001827506
Offering snapshot reported Oct 7, 2020 · SEC filing
- Reported sold
- $115M Offering amount: $115M
- Investors reported
- 24 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 22, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 7, 2020 | Initial | $114,999,989 | No comparison | 24 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-377389
Source: Form D, filed Oct 7, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sandip Agarwala | Director |
| Nick Galakatos | Director |
| Suzanne Ildstad | Director, Executive |
| Geoff Mackay | Director |
| Mark Mc Dade | Director |
| Francois Nader | Director |
| Scott Requadt | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
201 E. Jefferson St., Suite 110 B
Louisville, KY, 40202
Louisville, KY, 40202